ArticlePatient preference and adherence2025
Development and Validation of a New Nomogram for Predicting Medication Nonadherence Risk in a Chinese Hyperlipidemia Population.
Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to explore the factors influencing medication adherence and develop a medication nonadherence risk nomogram in a Chinese population with hyperlipidemia. Methods: This prospective intervention study was conducted in Beijing from November 2020 to October 2021. Medication adherence was determined according to the 9-question scale and nonadherence patients were intervened by pharmacists and followed up for 3 months. Multivariate logistic regression was used to analyze the risk factors of medication nonadherence, and then a nomogram model was established. The concordance index (C-index), area under the curve (AUC) was used to evaluate the accuracy of the prediction model. The decision curve analysis (DCA) and clinical impact plot analysis were employed to further evaluate the clinical effectiveness of the nomogram. Results: A total of 685 patients were included for analysis. The rate of medication nonadherence was 238 patients (34.75%). Post-intervention, the average score of medication adherence increased from 20.75±8.01 to 29.90±6.93 (p < 0.001). And the number of patients with TC, TG, LDL-C, and HDL-C reaching the standard was 264 (62.86%), 201 (47.43%), 318 (78.52%), and 377 (96.71%), respectively. Five predictors including the course of hyperlipidemia (OR=2.957, 95% CI 1.168-7.488), following the doctor's advice to visit (OR=2.757, 95% CI 1.389-5.472), use of medications empirically (OR=1.189, 95% CI 1.188-2.786), physical exercise (OR=0.399, 95% CI 0.205-0.776) and lifestyle compliance (OR=0.910, 95% CI 0.839-0.988) were identified to build the nomogram model. The AUC was 0.927 and C-index was 0.87. Conclusion: Patients with hyperlipidemia displayed low medication adherence which pharmaceutical interventions can improve. We developed and validated a nomogram model to facilitate the individual medication nonadherence risk prediction in hyperlipidemia patients. Limitation: First, using the cut-off value of 27 for adherence assessment in the adherence questionnaire, criterion validity was not enough good to validly screen a patient with nonadherence to medication. Second, our study may have unmeasured confounding variables, which could bias the results. Third, owing to the lack of external validation in this study, it may have some limitations in extrapolation. Fourth, the questionnaire was assessed by self-report measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.